Search the Newsreel

Cubex Tubings standalone net profit rises 7.32% in the June 2026 quarter

Abacus Group (ASX:ABG) Dividend Watch: Can a 9.34% Yield Reflect Long-Term Income Potential?

Curtiss-Wright Shares Dropping 5.3% on Curtiss-Wright (CW) Q2 2026 Earnings Call Transcript

Curtiss-Wright Corporation's shares plunged 5.3% following its Q2 2026 earnings call, with the stock closing at $685.25 amidst elevated trading volume. The market reacted negatively to the company's disclosure, indicating investor concerns about management's commentary or guidance, though specific financial figures were not immediately …

Scully Royalty names interim CEO and CFO as chairman steps in during leadership search

Scully Royalty Ltd. has appointed Chairman Michael Smith as interim CEO and CFO, replacing Samuel Morrow, who will remain a non-executive director. Smith will oversee executive functions while the company searches for permanent leadership. The company has committed to maintaining disciplined financial oversight during …

ICU Medical (ICUI) investor to sell 5,417 shares worth $982K on NASDAQ

ICU Medical shareholder Daniel Woolson plans to sell 5,417 shares of common stock, valued at $982,264.61, on NASDAQ by August 13, 2026. This sale follows a previous transaction three months prior where Woolson sold 2,123 shares for $280,684.80. The shares originate from various performance …

NextCure stock rating reiterated at Buy by H.C. Wainwright

H.C. Wainwright reiterated a Buy rating and a $20.00 price target for NextCure Inc. (NASDAQ: NXTC) following investor enthusiasm surrounding its announced reverse merger with Avere Therapeutics. The combined entity will operate as Avere Therapeutics and trade as AVRX, with the transaction expected to …

5 Revealing Analyst Questions From CLEAR Secure’s Q2 Earnings Call

5 Revealing Analyst Questions From CLEAR Secure's Q2 Earnings Call CLEAR Secure's second quarter was marked by strong revenue growth and notable operating margin improvement, which contributed to a positive market reaction. Management attributed these results to increased adoption of its secure identity platform, …

Cue Biopharma, Inc. SEC Filing (Aug 14, 2026)

This article reports on a Form 144 SEC filing by Cue Biopharma, Inc. (CUE) on August 14, 2026. The filing indicates a proposed sale of 8,829 shares of common stock with an aggregate market value of $266,106.06, acquired through Restricted Stock Units vesting under …

Patrick Burnett Sells 6,700 Shares of Arcutis Biotherapeutics (NASDAQ:ARQT) Stock

Patrick Burnett, an insider at Arcutis Biotherapeutics (NASDAQ:ARQT), sold 6,700 shares of the company's stock for $174,736 on August 12th, reducing his direct stake by over 5%. This sale follows two earlier transactions in August where he sold an additional 9,255 shares. Despite the …

Marcus & Millichap arranges $3.9 million sale of 56,000 s/f 470 Pine St.

Marcus & Millichap successfully brokered the sale of 470 Pine St., a 56,000 square foot multi-tenant building in downtown Manchester, NH, for $3.9 million. The property, originally built in 1924 and converted from a mill to a school, is fully occupied by three educational …

Abacus Group to Mark Down Storage King Stake After Accounting Reclassification

This Mercury Systems Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday

This article highlights five new stock initiations by Wall Street analysts. Notably, Piper Sandler initiated coverage on Unusual Machines Inc., LightPath Technologies Inc., and Mercury Systems Inc. with an Overweight rating. Chardan Capital initiated QumulusAI Inc. with a Buy rating, and JP Morgan started …

Arcutis Biotherapeutics EVP, CMO Burnett sells $394,896 in stock By Investing.com

Patrick Burnett, EVP and CMO of Arcutis Biotherapeutics (NASDAQ:ARQT), sold shares worth $394,896 in two transactions on August 11 and 12, 2026, following the exercise of stock options. The company's shares have seen a 61.64% return over the past year, and recent Q2 2026 …

ICU Medical (ICUI) Q2 2026 Earnings Call Transcript

Clever Culture Systems Seeks ASX Quotation for 2.6 Million New Shares

CURIS INC SEC Filing (Aug 13, 2026)

This article reports on a CURIS INC SEC Filing dated August 13, 2026, which is a Notice of Effectiveness for Form S-1, with an effectiveness date of August 12, 2026, at 5:30 P.M. The filing has a neutral impact and sentiment according to AI-generated …

Could Arcus Biosciences (RCUS) and Summit Therapeutics (SMMT)’s Cancer Drug Partnership Create a New Treatment Standard?

On July 22, Arcus Biosciences, Inc. (NYSE:RCUS) and Summit Therapeutics Inc. (NASDAQ:SMMT) announced a major clinical trial collaboration to combine Arcus's casdatifan (an investigational HIF-2α inhibitor) with Summit's ivonescimab (an investigational PD-1/VEGF bispecific antibody). The study aims to evaluate the safety and efficacy of …

ICU Medical VP Daniel Woolson sells $982,264 in stock

Daniel Woolson, VP, GM-Infusion Capital at ICU Medical Inc. (NASDAQ:ICUI), sold 5,417 shares of the company's common stock for $982,264 on August 13, 2026, at $181.33 per share. This sale occurred as ICUI shares are near their 52-week high, following strong Q2 results where …

Arcus Biosciences (RCUS) Reported Q2 2026 Results, Is The Stock A Bargain?

Arcus Biosciences reported Q2 2026 results with $41 million in revenue and a $91 million net loss, along with new full-year revenue guidance. The stock has seen significant price returns (16.07% in 90 days, 24.35% YTD), and a current valuation suggests it is 24% …

Celcuity (CELC) Wins FDA Approval As Investors Weigh Whether The Pullback Is A Buying Opportunity

Celcuity (CELC) has received FDA approval for REVTORPYK for certain metastatic breast cancer patients and its inclusion in NCCN guidelines. Despite this positive news, the stock has experienced a significant pullback, falling 22% over 30 days and 37.1% over 90 days. Analysts currently value …

Celcuity Q2 Earnings Call Highlights

Key Points Interested in Celcuity, Inc.? Here are five stocks we like better. REVTORPYK launch remains on track: Celcuity expects commercial shipments of its FDA-approved gedatolisib therapy for certain advanced breast cancer patients to begin in late Q3 2026. The treatment has a $30,000 …

CURI | CuriosityStream Inc. Class A Financials - Revenue Breakdown

CELCUITY ($CELC) Releases Q2 2026 Earnings

ICU Medical (ICUI) officer Daniel Woolson sells 5,417 shares at $181.33

Daniel Woolson, VP and GM-Infusion Capital at ICU Medical Inc. (ICUI), sold 5,417 shares of common stock at $181.33 per share on August 13, 2026. After this transaction, Woolson directly holds 17,062 shares of ICU Medical common stock. The sale was not conducted under …

Citi Maintains Acumen Pharmaceuticals(ABOS.US) With Buy Rating, Maintains Target Price $4

Citi has reiterated its Buy rating for Acumen Pharmaceuticals (ABOS.US) and maintained its target price at $4. This continued endorsement suggests the analyst firm sees ongoing potential or stability in the company's financial outlook and stock performance.

Form 8K Securitize Corp For: 13 August By Investing.com

This article reports on the filing of Form 8K by Securitize Corp on August 13. The brief piece from Investing.com serves as a notification regarding this SEC filing. No further details about the content of the Form 8K are provided.

CELC: FDA approval, strong trial data, and robust cash position set stage for late Q3 launch

Celcuity Inc. (CELC) received FDA approval for REVTORPYK for HR-positive, HER2-negative advanced breast cancer, supported by strong trial data and NCCN guideline inclusion. Despite a Q2 net loss of $78.9M, the company has a robust cash position due to a $575M convertible note, setting …

Earnings call transcript: Celcuity Q2 2026 loss widens as launch nears

DocuSign climbs as investors appear to lean on prior beat-and-raise results ahead of next earnings

DocuSign (DOCU) shares rose 9.6% due to continued investor optimism following its recent quarterly earnings beat and increased full-year outlook. The surge may also reflect positioning ahead of the company's next earnings report, with strong profitability and revenue guidance from the previous update influencing …

Celcuity Inc. (NASDAQ: CELC) deepens loss as it raises $575M in converts

Is 4D Molecular Therapeutics Inc (FDMT) Undervalued After Q2 Ear

Celcuity beats second quarter loss estimates

Celcuity Inc. reported an adjusted loss of $1.07 per share for the second quarter of 2026, surpassing analyst estimates. The company's shares rose 1% after the announcement, driven by the recent FDA approval of its breast cancer treatment, REVTORPYK. Celcuity expects to begin shipments …

Securitize Corp. (SECZ) completes SPAC merger, raises $197.8M PIPE

Securitize Corp. (SECZ) has completed its SPAC merger with Cantor Equity Partners II, Inc. and Old Securitize, raising approximately $197.8 million through a PIPE investment. The company, now trading on the NYSE under SECZ, reported 163,265,685 common shares outstanding post-merger. Management also identified material …

Atlanticus Holdings Corporation Declares Quarterly Dividend on Series B Cumulative Perpetual Preferred Stock

Atlanticus Holdings Corporation announced a quarterly dividend of $0.476563 per share for its Series B Cumulative Perpetual Preferred shareholders, payable on or about September 15, 2026, to shareholders of record by September 1, 2026. The company focuses on providing inclusive financial services and has …

4D Molecular Therapeutics (NASDAQ:FDMT) Announces Quarterly Earnings Results

Mizuho Financial Group (UYSC) discloses 6.1% ownership stake in UY Scuti

Mizuho Financial Group has disclosed a 6.1% ownership stake in UY Scuti Acquisition Corp. (UYSC), totaling 469,800 common shares. The filing, an amended Schedule 13G, indicates that Mizuho holds sole voting and dispositive power over these shares, with Mizuho Securities USA LLC directly holding …